Management of psoriasis and risk and severity of COVID-19 infection in systemic, biologic and topical treatment for psoriasis during the COVID-19 pandemic: an epidemiological cohort study

Management of psoriasis and risk and severity of COVID-19 infection in systemic, biologic and topical treatment for psoriasis during the COVID-19 pandemic: an epidemiological cohort study - PsoCovid

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON51144

Enrollment

1500

Registered

2021-03-15

Start date

2021-04-15

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Subject is able to sign the informed consent form. * Age of 18 years or older * Subject is currently being treated for psoriasis with: o Conventional systemic immunosuppressive therapy (CSIT) including: methotrexate, cyclosporin A or fumaric acid. Concomitant topical therapy is allowed. o Biological immunosuppressive therapy (BIT) including, but not limited to: anti IL-17a, anti IL-23 or anti TNF-alpha biological agents. Concomitant topical therapy is allowed. Combination with low dose MTX is allowed o Topical therapy (TT) including corticosteroids, anthralin, calcipotriene, topical vitamin D derivatives, retinoids, urea and medicated shampoos

Exclusion criteria

Exclusion criteria: * Subject is being treated with immunosuppressive therapy for any indication other than psoriasis * Subject is incapacitated or otherwise incapable of participating in the study.

Design outcomes

Primary

Measure	Time frame
The point-prevalence of COVID-19 infection in the 3 treatment groups Risk ratios and confounder corrected odds ratio for treatment with biologics or conventional systemics vs. topical therapies regarding the risk of COVID-infections.	—

Secondary

Measure	Time frame
Proportion of severe COVID-19 infection in infected patients in the 3 treatment groups Patient satisfaction with their management by their dermatologist with a visual analogue scale. Patient satisfaction with different modes of teleconsultations with a visual analogue scale. Psoriasis disease activity change during this period on a with a visual analogue scale. Proportions of patients who stayed on treatment, changed treatment or stopped treatment due to Covid-19 infection (fear) with or without consent of their treating dermatologist.	—

Measure

Time frame

Proportion of severe COVID-19 infection in infected patients in the 3 treatment groups Patient satisfaction with their management by their dermatologist with a visual analogue scale. Patient satisfaction with different modes of teleconsultations with a visual analogue scale. Psoriasis disease activity change during this period on a with a visual analogue scale. Proportions of patients who stayed on treatment, changed treatment or stopped treatment due to Covid-19 infection (fear) with or without consent of their treating dermatologist.

—

Countries

Netherlands

Outcome results